Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial
Atul Malhotra(Monash Health), Mathijs C. Bunck(Eli Lilly (United States)), Scott A. Sands(Brigham and Women's Hospital), Ingo Fietze(Humboldt-Universität zu Berlin), Susan Redline(Harvard University), Terri E. Weaver(University of Illinois Chicago), Sujatro Chakladar(Eli Lilly (United States)), Ali Azarbarzin(Brigham and Women's Hospital), Julia P. Dunn(Eli Lilly (United States)), Richard J. Schwab(California University of Pennsylvania), Josef Bednařík(Eli Lilly (United States)), Ronald R. Grunstein(Royal Prince Alfred Hospital)
Cited by 78
Related Papers
Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events
|Journal of Clinical Sleep Medicine|2012|5.2k
Cohort Profile: The Study of Health in Pomerania
|International Journal of Epidemiology|2010|1k